Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 5/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CDC25A | P30304 | 3/20 | 0.52 |
| ▸ | CDC25B | P30305 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALPG | P10696 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3071327 | 0.93 | LMNA (0.60) | MAPTLMNARXFP1SMN1; SMN2POLB | |
| SCHEMBL3074301 | 0.89 | TP53 (0.53) | MAPTLMNARXFP1SMN1; SMN2POLB | |
| SCHEMBL7746877 | 0.89 | MAPT (0.50) | MAPTLMNARXFP1SMN1; SMN2POLB | |
| SCHEMBL13856857 | 0.85 | TP53 (0.61) | MAPTRXFP1POLBTP53NPSR1 | |
| SCHEMBL12325796 | 0.83 | ALDH1A1 (0.52) | MAPTLMNASMN1; SMN2POLBNPSR1 | |
| SCHEMBL6489608 | 0.81 | SMN1; SMN2 (0.51) | LMNASMN1; SMN2NPSR1ALDH1A1HTT | |
| Water SCHEMBL1905418 | 0.81 | SMN1; SMN2 (0.50) | MAPTLMNASMN1; SMN2NPSR1ALDH1A1 | |
| Water SCHEMBL1905420 | 0.81 | SMN1; SMN2 (0.50) | MAPTLMNASMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL3072473 | 0.80 | ALDH1A1 (0.52) | MAPTLMNASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL6192068 | 0.77 | MAPT (0.91) | MAPTLMNARXFP1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030171403-A1 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2003-09-11 | — | — | US | claimed |
| US-20110230523-A1 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | PARATEK PHARMACEUTICALS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-7790761-B2 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2010-09-07 | — | — | US | disclosed |
| US-20090131401-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131401-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20060100248-A1 | Blockade of voltage dependent sodium channels | GARTHWAITE GITI | 2006-05-11 | — | — | US | disclosed |
| US-7009056-B2 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2006-03-07 | — | — | US | disclosed |
| US-20030171403-A1 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2003-09-11 | — | — | US | disclosed |
| EP-1252156-A1 | BLOCKADE OF VOLTAGE DEPENDENT SODIUM CHANNELS | University College London (GB) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001057024-A1 | BLOCKADE OF VOLTAGE DEPENDENT SODIUM CHANNELS | UNIVERSITY COLLEGE LONDON (GB) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171403-A1 | Blockade of voltage dependent sodium channels | CACNA1F, SCNN1B, CACNA1B | MAPT 1326/4885LMNA 2371/4885RXFP1 1496/4885 |
| US-20090131401-A1 | Transcription factor modulating compounds and methods of use thereof | JUN, CREBBP, TFEB | MAPT 4415/4885LMNA 3323/4885RXFP1 1535/4885 |
| US-20060100248-A1 | Blockade of voltage dependent sodium channels | CACNA1I, CACNA1F, CACNA1C | MAPT 1289/4885LMNA 1882/4885RXFP1 1676/4885 |
| US-20110230523-A1 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | JUN, CREBBP, TFEB | MAPT 4415/4885LMNA 3323/4885RXFP1 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.